Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that the treatment met its primary endpoint, demonstrating efficacy in the patient population.
Dazodalibep was acquired through Amgen's purchase of Horizon Therapeutics and has shown promise in addressing the unmet medical needs of patients suffering from this autoimmune condition.
Amgen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE”
SEC Filing — AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
SupportCorroborates it
“<figure><div><img”
biopharma dive — Amgen reports a Phase 3 win with Sjögren’s drug candidate